||Selective Internal Radiation Therapy (SIRT)/Radioembolization
||Radiation Therapy & Nuclear Medicine
||August 1, 2018
||July 30, 2018
Selective internal radiation therapy (SIRT), also known as radioembolization with microsphere brachytherapy device (RMBD) and transarterial radioembolization (TARE), is a form of arterially directed therapy for primary and secondary liver cancer. The treatment involves catheter-based injection of radioactive Yttrium-90 (90Y) microspheres, in either glass or resin form, through the arterial branch feeding the affected portion of the liver.
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
|Policy Position Coverage is subject to the specific terms of the member’s benefit plan.|
SIRT, using radioactive Yttrium-90 (90Y) microspheres, may be considered medically necessary in an individual with:
- Unresectable and/or medically inoperable primary or metastatic liver malignancies
- Unresectable liver only or liver dominant metastases from neuroendocrine tumors (e.g., carcinoids, pancreatic islet cell tumors, endocrine tumor); or
- Unresectable primary hepatocellular carcinoma (HCC); or
- Unresectable metastatic liver tumors from primary colorectal cancer; or
- Requests for the treatment of liver metastases from other primary malignancies, including breast carcinoma, ocular melanoma, cutaneous melanoma, and intrahepatic cholangiocarcinoma, will be considered on a case-by-case basis.
- These requests should be based on the lack of any known systemic or liver-directed treatment options for this individual in an effort to relieve symptoms and/or possibly extend life expectancy; and
- The tumor burden should be liver dominant, not necessarily exclusive to the liver ; and
- Eastern Cooperative Oncology Group (ECOG) performance status should be zero (0) or one (1) or Karnofsky Performance Status (KPS) of 70 or more; and
- Life expectancy should be at least 3 months.
SIRT, as a debulking agent, is considered experimental/investigational, and therefore, non-covered because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature.
|37243, 75894, 77399, 77778, 79445, S2095|
Note: All requests for repeat radioembolization are subject to medical review and will be judged on a case-by-case basis
Repeat radioembolization may be considered medically necessary for new or progressive primary or metastatic liver cancers when ALL of the following are met:
- The individual has had a previous satisfactory response to an initial radioembolization treatment as evidenced on results of a computed tomography (CT) scan or positron emission tomography (PET)-CT scan performed 3 months following the previous procedure. Response should be graded according to the revised RECIST guideline (Version 1.1); and
- The disease still must be liver dominant; and
- Life expectancy of at least 3 months; and
- ECOG performance status no greater than two (2) or KPS of 70 or more; and
- There are no other effective systemic or liver-directed treatment options; and
- The individual has compensated liver function tests (LFTs); and
- Estimated lung dose and combined lung dose from previous embolizations are within acceptable dose volume constraints.
- Exclude an individual with lung shunting in which the lung radiation dose is greater than 35 to 30 Gy per treatment or greater that 50 Gy cumulatively for all treatments; and
- Treatment should be given to a targeted tumor volume.
Repeat whole liver irradiation is considered experimental/ investigational, and therefore, non-covered because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature.
A third radioembolization is considered experimental/ investigational, and therefore, non-covered because the safety and/or effectiveness of this service cannot be established by the available published peer-reviewed literature.
|77261, 77262, 77263, 77280, 77285, 77290, 77300, 77370, 77470, 77750, 77778, S2095 |
- Inability to catheterize the hepatic artery
- Fulminant liver failure (Childs-Pugh status late B or C)
- 99mTechnetium-Albumin Macroaggregates (99mTc-MAA) hepatic arterial perfusion scintigraphy demonstrating significant reflux or non-target deposition to the gastrointestinal organs that cannot be cannot be corrected by angiographic techniques.
- It is important that liver injection of 99mTc-MAA is delivered with flow rates and catheter position that mimic the anticipated 90Y infusion rate catheter position
- 99mTc-MAA hepatic arterial perfusion scintigraphy demonstrating the potential greater than 30 Gy radiation exposure to the lung
- Excessive tumor burden in the liver with greater than 70% of the parenchyma replaced by tumor
- Prior extensive liver resection
- Total bilirubin greater than 2 mg/dL in the absence of reversible cause (e.g. obstruction), which indicates severe liver function impairment
- Nonobstructive bilirubin elevations generally indicate that liver metastases have caused liver impairment to a degree at which risks outweigh benefits for this therapy
- In contrast, patients with hepatocellular carcinoma (HCC) and elevated bilirubin may be treated with radioembolization if a segmental or subsegmental infusion can be performed
- Prior radiation therapy to the liver or upper abdomen that included a significant volume of the liver
- Based on a study by Lam et al. (2013) the fraction of liver exposed to greater than 30 Gy (V30) is the strongest predictor of hepatotoxicity. All patients with V30 greater than 13% experienced hepatotoxicity
- Concurrent or prior capecitabine chemotherapy (within the previous two months)
- If the patient is known to be pregnant, the potential radiation risks to the fetus and clinical benefits of the procedure required before, during, and after RMBD, and any scatter radiation from the hepatic implant should be considered before proceeding with treatment
- Portal vein thrombosis (PVT):
- Tsi et al. suggests 90Y microspheres are tolerated in patients with HCC and major PVT
- Kulik et al. (2008) reported more grade 3/4 adverse events in patients with main portal vein thrombosis
- Schwartz et al. (2010) states 90Y is a safe microembolization treatment that can be used as an alternative to TACE in patients in case of PVT
|Place of Service: Outpatient|
Experimental/Investigational (E/I) services are not covered regardless of place of service.
SIRT is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
|The policy position applies to all commercial lines of business|
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect Highmark's reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.
Discrimination is Against the Law
The Claims Administrator/Insurer complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The Claims Administrator/Insurer does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. The Claims Administrator/ Insurer:
If you need these services, contact the Civil Rights Coordinator.
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
- Qualified interpreters
- Information written in other languages
If you believe that the Claims Administrator/Insurer has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, P.O. Box 22492, Pittsburgh, PA 15222, Phone: 1-866-286-8295, TTY: 711, Fax: 412-544-2475, email: CivilRightsCoordinator@highmarkhealth.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.
You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)
Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.
Insurance or benefit/claims administration may be provided by Highmark, Highmark Choice Company, Highmark Coverage Advantage, Highmark Health Insurance Company, First Priority Life Insurance Company, First Priority Health, Highmark Benefits Group, Highmark Select Resources, Highmark Senior Solutions Company or Highmark Senior Health Company, all of which are independent licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans.
Highmark retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.